Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07123155 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study of S-606001 as an Add-on to Enzyme Replacement Therapy (ERT) in Participants With Late-onset Pompe Disease (LOPD)

StatusRecruiting
PhasePhase 2
SponsorShionogi
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Site details revised at 1 of 28 sitesv17
  2. Site details revised at 2 of 28 sitesv16
  3. Site details revised at 2 of 28 sitesv15
  4. Site details revised at 1 of 28 sitesv14
  5. Site details revised at 2 of 28 sitesv13
Show 11 earlier versionsHide 11 earlier versions
  1. Site details revised at 1 of 28 sitesv12
  2. Site details revised at 1 of 28 sitesv11
  3. Study sites revised (28)v10
  4. Site details revised at 1 of 28 sitesv9
  5. Site details revised at 3 of 28 sitesv8
  6. Site details revised at 1 of 28 sitesv7
  7. Site details revised at 1 of 28 sitesv6
  8. Site details revised at 5 of 28 sitesv5
  9. Site details revised at 2 of 28 sitesv4
  10. Trial status: Not Yet Recruiting to Recruiting
    • Site details revised at 28 of 28 sites
    v3
  11. Study sites: 0 to 28v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Shionogi
45 trials monitored
See 2 trials at risk
The purpose of this study is to evaluate the safety, pharmacodynamics (PD), and exploratory clinical efficacy of S-606001 in adult participants with LOPD as an add-on to ERT.
Trial Details
NCT Number NCT07123155
Lead Sponsor Shionogi
Conditions
(from sponsor)		 Pompe Disease
Related terms Glycogen Storage Disease, Glycogen Storage Disease Type II, Rare Diseases
Enrollment 45 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov